NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 04:05 pm EDT
Share
NovaBay Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 4.61 million compared to USD 3.66 million a year ago. Net loss was USD 2.04 million compared to USD 2.16 million a year ago. Basic loss per share from continuing operations was USD 44.45 compared to USD 50.05 a year ago. Diluted loss per share from continuing operations was USD 44.45 compared to USD 50.05 a year ago.
For the six months, revenue was USD 7.73 million compared to USD 6.94 million a year ago. Net loss was USD 3.78 million compared to USD 2.27 million a year ago. Basic loss per share from continuing operations was USD 77.35 compared to USD 53.9 a year ago. Diluted loss per share from continuing operations was USD 77.35 compared to USD 53.9 a year ago.
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and wound care products. Its product, Avenova Antimicrobial Lid and Lash Solution, has antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. It offers a portfolio of products for each step of the standard at home treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. It also manufactures and sells its proprietary form of hypochlorous acid for the wound care market with its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries.
NOVABAY PHARMACEUTICALS, INC. 
